UNSPSC 51363600: Hypnotic oximes

This classification denotes antibiotics derived from hydroxylamine + (X-aldehyde) or (X-ketone) for the structure RX-RY-C=NOH where RY is typically oxygen and RX constitutes an organic side-chain, sometimes also called aldoximes, the majority of which are cholinesterase reactivators.

UNSPSC 51363600 Hypnotic oximes is a Class code, but the recent state and local opportunities posted under this code do not align with its nominal scope. Instead, jurisdictions are using the code to procure naloxone, generic pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription programs—none of which are hypnotic oximes. The actual work being solicited reflects demand for opioid-overdose response supplies, broad-based pharmaceutical distribution through cooperative purchasing networks, and pharmacy benefit innovation rather than sedative or anesthetic compounds. State and local issuing bodies purchasing under this code include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. Seminole County, Florida, in particular, is seeking annual supplies of naloxone and drug deactivation systems to support community health initiatives with quarterly deliveries, while the Texas Health and Human Services Commission is exploring direct-to-manufacturer prescription fulfillment models to improve cost management and efficiency. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administers the broadest recent procurement, establishing multiple-award contracts for generic pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota, Oregon, and other member jurisdictions.

Recent activity concentrates in Florida, Texas, and Minnesota. Seminole County's IFB for naloxone and drug deactivation systems (posted June 30, 2026, due July 26, 2026) seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; vendors must submit bids electronically and include all shipping costs. The Texas HHS Commission issued an RFI (posted April 3, 2026, due April 3, 2026) to gather market intelligence on direct-to-manufacturer prescription programs before launching a formal RFP. MMCAP's RFP for generic multi-source pharmaceuticals and OTC products (posted January 20, 2026, due March 26, 2026) requires vendors to supply through three authorized wholesalers, comply with cGMP and Drug Supply Chain Security Act standards, maintain $5 million commercial general liability insurance, and accept a 3 percent administrative fee on all purchases. The code shows limited and misaligned recent activity; the mismatch between the nominal commodity scope and what is actually being procured suggests this code may not be the primary taxonomy vehicle for pharmaceutical procurement at state and local level.